Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials

The purpose of the present study was to quantify the cumulative randomized evidence for the efficacy and safety of lapatinib combined with neoadjuvant therapy in human epidermal growth factor receptor (HER) 2-positive breast cancer. Three electronic databases, MEDLINE, Embase and Cochrane Central Re...

Descripción completa

Detalles Bibliográficos
Autores principales: SUN, JINZHONG, CHEN, CHUANG, YAO, XIAOLI, SUN, SHENGRONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315003/
https://www.ncbi.nlm.nih.gov/pubmed/25663912
http://dx.doi.org/10.3892/ol.2015.2848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315003/
https://www.ncbi.nlm.nih.gov/pubmed/25663912
http://dx.doi.org/10.3892/ol.2015.2848

Ejemplares similares